Latest Articles

Publication Date
Faeth Therapeutics’ $92 Million Total Funding Powers PIKTOR Phase 2 - citybiz

Faeth Therapeutics’ $92 Million Total Funding Powers PIKTOR Phase 2 citybiz

Published: Oct. 20, 2025, 1:40 p.m.
Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer - Business Wire

Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer Business Wire

Published: Oct. 20, 2025, noon
Shaoyao Gancao Decoction: a comprehensive review of modern clinical applications and underlying pharmacological mechanisms.

Shaoyao Gancao Decoction, a classic formula from Zhang Zhongjing in the Han Dynasty, has the effects of regulating the function of the liver, relieving spasm and stopping pain. Traditionally, it …

Published: Oct. 20, 2025, midnight
Catamenial Pneumothorax Without Thoracic Endometriosis: A Case Report From the Gulf Cooperation Council (GCC) Region - Cureus

Catamenial Pneumothorax Without Thoracic Endometriosis: A Case Report From the Gulf Cooperation Council (GCC) Region Cureus

Published: Oct. 19, 2025, 12:43 a.m.
Victoria’s Secret Spotlight: Dylan Sprouse and Barbara Palvin Champion Women’s Health and Precancer Diseases Awareness - Oncodaily

Victoria’s Secret Spotlight: Dylan Sprouse and Barbara Palvin Champion Women’s Health and Precancer Diseases Awareness Oncodaily

Published: Oct. 18, 2025, 9:25 p.m.
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen - The AI Journal

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen The AI Journal

Published: Oct. 18, 2025, 10:28 a.m.
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen - Business Wire

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen Business Wire

Published: Oct. 18, 2025, 10 a.m.
[Endometriosis management in the emergency department: a diagnostic and therapeutic challenge].

Endometriosis affects at least one in ten women of childbearing age, yet it is often overlooked in emergency care. Clinicians should consider this diagnosis for any woman presenting with menstrual …

Published: Oct. 18, 2025, midnight
Addressing Meta-Inflammation in the Comprehensive Management of Chronic Pain.

Chronic pain is a widespread condition affecting millions globally, placing significant strain on healthcare systems, as evidenced by the current opioid crisis. Despite advances in pain management, conventional treatments often …

Published: Oct. 18, 2025, midnight
Catamenial Pneumothorax Without Thoracic Endometriosis: A Case Report From the Gulf Cooperation Council (GCC) Region.

Catamenial pneumothorax is a rare clinical condition first described over seven decades ago. It typically occurs within 72 hours before or after menstruation and is most frequently observed in women …

Published: Oct. 18, 2025, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!